Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anitocabtagene Autoleucel in Newly Diagnosed Multiple Myeloma
NCT07045909Phase 2Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of anitocabtagene autoleucel in multiple myeloma (MM) (3 cohorts), sponsored by Fundación PETHEMA. Primary endpoints: Incidence and severity of all adverse events at 3 years and Undetectable minimal residual disease negative-CR rate at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07045909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07045909.